Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis

Zhang, Shumeng; Yan, Bing; Zheng, Jing; Zhao, Jingbo; Zhou, Jianying

doi:10.18632/oncotarget.11494

Cited by 7 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…196 ROS1 fusion is found in 1-2% of lung adenocarcinoma and these patients are usually younger with a median age of 48.9 years, nonsmokers, female, Asian and in the advanced setting. [197][198][199] A total of 36% of patients with ROS1 fusions presented with brain metastases, which was similar to that reported in ALK and other driver-mutationpositive mNSCLC. 200 Ng and colleagues also reported a higher incidence of thromboembolic disease in patients with ROS1 (34.7%) than patients with ALK (22.3%), EGFR (13.7%) or K-RAS (18.4%) mutations.…”

Section: Ros1 Fusionsupporting

confidence: 79%

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Chu

2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.

show abstract

Section: Ros1 Fusionsupporting

confidence: 79%

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Chu

2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…In recent years, various biological markers, such as the nucleotide excision repair pathway, cell-cycle regulators, β-tubulin class III, epidermal growth factor receptor mutations, and gene expression profiling, have been explored to predict the efficacy of traditional chemotherapies in patients with lung cancer [ 37 , 38 ]. To further explore the relationship between the PD pathway and the therapeutic response or survival of pemetrexed-treated patients, we performed the Kaplan-Meier method and multivariate Cox regression analysis.…”

Section: Discussionmentioning

confidence: 99%

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed

Zhang

Bao

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

Conventional chemotherapy for lung cancer exerts anti-tumor effects through cytotoxicity, and through immunologic regulation by reducing specific T cell subsets and inducing the expression of programmed death ligand 1 (PD-L1) on tumor cells. Even though pemetrexed has shown huge potential in combination with other targeted or immune therapies, there is still little information about the values of specific immune checkpoint markers for advanced lung adenocarcinoma treated with pemetrexed. In the present study, a total of 56 patients with advanced lung adenocarcinoma, who received pemetrexed-based chemotherapy, were included retrospectively. Immunohistochemistry was performed to assess PD-L1, programmed death 1 (PD-1), thymidylate synthase, and tumor infiltrating lymphocytes (TILs). In this cohort, the positive expression of PD-L1 and PD-1 were 26.8% and 33.9% respectively. PD-L1, PD-1, and thymidylate synthase expression were not significantly associated with any clinical features, while the expression of both PD-L1 and PD-1 were correlated with Ki-67 expression. Furthermore, the expression of PD-1 was significantly correlated with TILs. The progression-free survival (PFS) in patients with PD-L1+ specimens was significantly longer compared to PD-L1− specimens. Moreover, PD-L1 expression was an independent protective factor for PFS, and the smoking status was an independent risk factor. PD-L1 expression was significantly associated with better prognosis for patients with pemetrexed-based treatment. Our findings suggested that PD-L1 expression might be a favorable prognostic biomarker for pemetrexed-based regimen, which is a rationale for combining immunotherapy with chemotherapy for lung cancer.

show abstract

“…This could be due to the predominance of advanced stadium samples, so that patients with stage N tend to be numerous. Research conducted by Zhang et al (14) in a cohort of 280 patients with 133 men…”

Section: Discussionmentioning

confidence: 99%

Bone metastases tend to increase in non-small cell lung cancer with epidermal growth factor receptor mutation

et al. 2022

View full text Add to dashboard Cite

BackgroundIncreased understanding in molecular pathology of advanced non-small cell lung cancer (NSCLC) over the past decades has led to personalized treatment approaches being advocated. Epidermal growth factor receptor (EGFR) mutation that often occurs in NSCLC can be identified using immunohistochemical examinations. Moreover, clarifying the relationship between computed tomography (CT) and EGFR mutation of NSCLC might inform therapeutic decision-making. The purpose of this study was to determine the relationship between metastatic sites on primary chest CT-scan and EGFR mutation in NSCLC lung cancer patients. MethodsAn cross-sectional design using secondary data was conducted, involving 76 NSCLC patients. EGFR mutations were determined by immunohistochemical examination and metastatic sites by chest CT-scan with contrast. The collected metastatic sites comprised hilar and mediastinal lymphadenopathy, pulmonary nodules, and bone, liver, spleen and suprarenal metastases. A Chi square test was used to analyze the data. ResultsThis study revealed that the highest NSCLC stage was IVb, found in 39 samples (51.3%), while 34 (44.7%) subjects had EGFR mutation. There was no statistically significant difference between metastatic site and positive EGFR mutation, although positive bone metastases (54.8%) tend to have more numerous positive EGFR mutations compared to negative bone metastases (37.7%) (p=0.142). ConclusionsPatients with positive bone metastases tend to have higher positive EGFR mutation compared to negative bone metastases in NSCLC lung cancer patients. Prospective studies evaluating patients with EGFR mutation for bone metastases should be considered. This can provide information on therapeutic decision-making to obtain good clinical outcomes.

show abstract

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis

Cited by 7 publications

References 25 publications

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed

Bone metastases tend to increase in non-small cell lung cancer with epidermal growth factor receptor mutation

Contact Info

Product

Resources

About